TGA pre submission meetings were originally booked for November so hopefully these are happening shortly with full study results to follow (I suspect they are holding on to these until engagement with TGA).
With flower and capsule products beginning to sell on top of existing Medicabilis products, a reduced admin cost base, studies in Malaysia supporting sales early next year and C-Fit studies progressing towards commercial sales for Aquaphase - exciting times for BOD particularly at a market cap of <$5m. S3 year one gross profits alone are more than likely to eclipse this based on industry estimates of the OTC market and standard industry margins.
Despite the ongoing funding risks, it’s a strong buy for me at this price. If regulatory hurdles are cleared, which we should have more assurance on soon, this will fly.
- Forums
- ASX - By Stock
- Ann: Bod Science announces placement to raise A$2m
TGA pre submission meetings were originally booked for November...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOD (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BOD (ASX) Chart |
Day chart unavailable
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online